NCT02589847View on ClinicalTrials.gov

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

272

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

March 31, 2019

Conditions

Clostridium Difficile Infection

Interventions

BIOLOGICAL

RBX2660

suspension of intestinal microbes

DRUG

Standard of Care Antibiotics

Standard of Care Antibiotics

Trial Locations (30)

10468

The Bronx

11355

Flushing

14618

Rochester

22150

Springfield

23454

Virginia Beach

32610

Gainesville

33065

Coral Springs

33101

Miami

33744

Bay Pines

38305

Jackson

40506

Lexington

45801

Lima

46260

Indianapolis

47904

Lafayette

48202

Detroit

52325

Syracuse

55130

Saint Paul

55905

Rochester

58122

Fargo

60153

Maywood

60637

Chicago

63110

St Louis

68198

Omaha

72117

North Little Rock

77025

Houston

83404

Idaho Falls

85054

Phoenix

95817

Sacramento

V5Z1M9

Vancouver

L8N4A6

Hamilton

All Listed Sponsors

lead

Rebiotix Inc.

INDUSTRY

NCT02589847 - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection | Biotech Hunter | Biotech Hunter